-
Biopolymer Engineering, Inc., v. Immunocorp et al DC CAFC
- 0:05-cv-00536
- D. Minn.
- Judge: Joan N. Ericksen
+1
- Filed: 03/14/2005
- Closed: 09/02/2009
- Latest Docket Entry: 05/05/2011
- PACER
2
Plaintiffs
3
Defendants
4
Accused
Products
14
Patents-in-Suit
1,634
Days in
Litigation
-
Biopolymer Engineering, Inc., v. Immunocorp et al DC CAFC
- 0:05-cv-00536
- D. Minn.
- Judge: Joan N. Ericksen
+1
- Filed: 03/14/2005
- Closed: 09/02/2009
- Latest Docket Entry: 05/05/2011
- PACER
Causes of Action
Infringement
Unfair Competition
Willful Patent Infringement
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
Claim | Outcome |
---|---|
All challenged claims |
Valid (102)
Entry 361 |
Claim | Outcome |
---|---|
All challenged claims |
Valid (102)
Entry 361 |
Claim | Outcome |
---|---|
All challenged claims |
Valid (102)
Entry 361 |
Claim | Outcome |
---|---|
All challenged claims |
Valid (102)
Entry 361 |
Claim | Outcome |
---|---|
All challenged claims |
Valid (102)
Entry 361 |
Claim | Outcome |
---|---|
All challenged claims |
Valid (102)
Entry 361 |
Claim | Outcome |
---|---|
All challenged claims |
Valid (102 and 103)
Entry 361 |
-
Infringement
Biotec Pharmacon ASA
- 12 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
ImmudermImmupetImmutolSoluble beta glucan | US 4,962,094 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 4,992,540 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,037,972 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,532,223 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,576,015 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,622,939 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,702,719 A | All Asserted Claims |
No infringement
Entry 447Entry 361 |
ImmudermImmupetImmutolSoluble beta glucan | US 5,783,569 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,811,542 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,817,643 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 6,020,324 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 6,143,731 A | All Asserted Claims |
No infringement
Entry 361
|
Immuno Corporation
- 12 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
ImmudermImmupetImmutolSoluble beta glucan | US 4,962,094 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 4,992,540 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,037,972 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,532,223 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,576,015 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,622,939 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,702,719 A | All Asserted Claims |
No infringement
Entry 447Entry 361 |
ImmudermImmupetImmutolSoluble beta glucan | US 5,783,569 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,811,542 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 5,817,643 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 6,020,324 A | All Asserted Claims |
No infringement
Entry 361
|
ImmudermImmupetImmutolSoluble beta glucan | US 6,143,731 A | All Asserted Claims |
No infringement
Entry 361
|